Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
World Conference on Lung Cancer (WCLC)
WCLC 2016
Mini Oral Session 1: Improvement and Implementation of Lung Cancer Screening
WCLC 2016
Summaries of the following research efforts will be presented during Mini Oral Session 1:
Detection of Lung Cancer and
EGFR
Mutations by Electronic Nose System. Shlomi D, et al. Researchers found that breath analysis could discriminate between lung cancer and benign pulmonary nodules, and between
EGFR
-positive and -negative mutations. In the future, a portable, inexpensive, simple device may be a viable way to evaluate pulmonary nodules.
Non-Invasive LuCED
®
Test for Endobronchial Dysplasia, Enabling Chemoprevention Therapy with Drugs Such as Iloprost. Meyer M, et al. Identification of endobronchial lung dysplasia with a noninvasive sputum-based test could facilitate chemoprevention. Researchers evaluated a novel test for early-stage lung cancer to learn if it can identify tumor cells that have been exfoliated into sputum. They concluded that the LuCED test can detect endobronchial dysplasia in the lung with an estimated 98% case sensitivity and 95% case specificity.
Predictive Performances of NELSON Screening Program Based on Clinical, Metrological and Population Statistics. Beaumont H, et al. Researchers tested a simulation of the NELSON triage algorithm by using published statistics as input data: nodule size distribution, nodule growth distribution, and the precision of nodule volume measurements. They discerned markedly different test performance for size versus growth assessment of the NELSON triage algorithm. Future work is designed to optimize triage algorithms in screening programs.
Mortality, Survival and Incidence Rates in the ITALUNG Randomised Lung Cancer Screening Trial (ITALY). Paci E, et al. Low-dose computed tomography (LDCT) screening for lung cancer is not yet recommended in Europe. This long-term study randomized 3206 eligible subjects to receive 4 annual LDCT scans (n = 1613) or usual care (n = 1593). Overall and lung-cancer–specific mortality were reduced by 17% and 30% in the LDCT versus control groups, respectively. Among the lung cancers diagnosed, a greater proportion of those in the LDCT group were stage I.
Related Items
Randomized Phase 3 Study of Osimertinib vs Platinum-Pemetrexed for Patients with EGFR T790M-Positive Advanced NSCLC After EGFR-TKI Therapy (AURA3)
World Conference on Lung Cancer (WCLC)
WCLC 2016
Nivolumab vs Nivolumab with Ipilimumab in Recurrent Small-Cell Lung Cancer (SCLC) (CheckMate 032)
World Conference on Lung Cancer (WCLC)
WCLC 2016
Subgroup Analyses from Randomized Phase 3 Study of Atezolizumab vs Docetaxel in Patients with Advanced NSCLC (OAK)
World Conference on Lung Cancer (WCLC)
WCLC 2016
First-Line Afatinib versus Gefitinib in EGFR-Mutated Advanced NSCLC: Updated Overall Survival (OS) Analysis of LUX-Lung 7
World Conference on Lung Cancer (WCLC)
WCLC 2016
Efficacy and Safety of Necitumumab Continuation After Triplet Therapy in Patients with EGFR-Expressing NSCLC (SQUIRE)
World Conference on Lung Cancer (WCLC)
WCLC 2016
Phase 3 Study of Alectinib vs Crizotinib in ALK-Positive NSCLC (J-ALEX)
World Conference on Lung Cancer (WCLC)
WCLC 2016
Phase 2 Study of Abemaciclib + Pembrolizumab in KRAS Mutation and PD-L1–Positive Metastatic NSCLC
World Conference on Lung Cancer (WCLC)
WCLC 2016
Pembrolizumab + Carboplatin and Pemetrexed as First-Line Therapy for Advanced NSCLC (KEYNOTE-021 Cohort G)
World Conference on Lung Cancer (WCLC)
WCLC 2016
Efficacy and Safety of Necitumumab plus Pembrolizumab in Patients Who Relapsed After Chemotherapy for Metastatic Nonsquamous NSCLC
World Conference on Lung Cancer (WCLC)
WCLC 2016
Randomized, Phase 3 Study of First-Line Ceritinib vs Chemotherapy in Patients with ALK-Positive NSCLC (ASCEND-4)
World Conference on Lung Cancer (WCLC)
WCLC 2016
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us